---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-122778"
form_type: "8-K"
ticker: "CGEM"
cik: "0001789972"
company_name: "Cullinan Therapeutics, Inc."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:43:47.037188+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cullinan Therapeutics Q3 net loss $40.6M; cash $639M; CLN-978 IND cleared for SLE Phase 1

## Summary
- Net loss $40.6M ($0.69/sh) vs $39.2M ($0.91/sh) in Q3 2023; cash $639M provides runway to 2028.
- CLN-978 (SLE) IND cleared in US and Australia; Phase 1 starts; initial data expected Q4 2025.
- Zipalertinib pivotal Phase 2b enrollment completed ahead of schedule; results mid-2025.
- CLN-619 expansion data in endometrial/cervical cancers expected Q2 2025; patent issued to 2041.
- R&D expense $35.5M, G&A $13.3M; both increased YoY from $33.8M and $11.0M respectively.

## SEC filing metadata
- accession: 0000950170-24-122778
- form_type: 8-K
- ticker: CGEM
- cik: 0001789972
- company_name: Cullinan Therapeutics, Inc.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1789972/000095017024122778/0000950170-24-122778-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1789972/000095017024122778/cgem-20241107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-122778
- JSON: https://secwatch.observer/filing/0000950170-24-122778.json
- Plain text: https://secwatch.observer/filing/0000950170-24-122778.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.